



For Immediate Release

viDA Therapeutics Announces Scientific Founder, Dr. David Granville Inducted into the Royal Society of Canada

Vancouver, British Columbia (CNW – September 29, 2014) viDA Therapeutics Inc. (viDA), a private biotechnology company, is pleased to announce that Dr. David Granville, viDA's scientific founder and Chief Scientific Officer, and Professor at the Centre for Heart Lung Innovation, St. Paul's Hospital, University of British Columbia, has been inducted into the College of New Scholars, Artists and Scientists of the Royal Society of Canada. Dr. Granville's groundbreaking research, including novel approaches to treat chronic inflammatory and age related diseases through the targeted inhibition of the serine protease family, Granzymes, has earned him a nomination by his peers for this highly prestigious honour. Those named to the College have been nominated by 51 Canadian universities and the National Research Council, and they represent the emerging generation of scholarly, scientific and artistic leadership in Canada. Dr. Granville is one of just two University of British Columbia researchers who became inaugural members of the College this year.

About viDA Therapeutics

viDA Therapeutics Inc. (viDA) is a biotechnology company advancing a platform of first-in-class therapeutics based on inhibitors to a well-characterized protease target, Granzyme B (GzmB), based on a new mechanism of action. viDA's lead program is the development of a topical treatment for a rare autoimmune skin disorder, Discoid Lupus Erythematosus (DLE). viDA is building a proprietary library of small molecules and biologics that target extracellular GzmB which is applicable to multiple therapeutic targets. Inhibition of extracellular GzmB has shown utility across many therapeutic indications and efficacy in a number of predictive models of disease including tissue repair, vascular, aging and inflammation. For more information, please visit www.vidatherapeutics.com.

Contact Info:

Alistair Duncan, BSc, CA,

President & CEO

viDA Therapeutics Inc.

Tel: 778-373-0916 or aduncan@vidatherapeutics.com